MaxCyte (MXCT) News
NASDAQ: MXCTHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
1.37+0.09 (+7.03%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MXCT news summary
We found 8 recent headlines mentioning MaxCyte (MXCT): 0 in the past week and 6 in the past 30 days, most often from Nasdaq, GlobeNewswire. MXCT is making an outsized move today, up 7.03% at $1.37, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "MaxCyte (MXCT) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest MaxCyte headlines
- MaxCyte (MXCT) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- MaxCyte To Acquire Akron(RTTNews) - MaxCyte, Inc. (MXCT) has entered into a definitive agreement to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management for total consideration of $151.8 million.…NasdaqMXCT, MKC.V
- MaxCyte, Inc. Q3 Loss Declines(RTTNews) - MaxCyte, Inc. (MXCT) released Loss for third quarter of -$4.76 millionNasdaqMXCT, MKC.V
- MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue GuidanceMaxCyte will host its third quarter 2026 earnings call today, November 10th, at 8:30 a.m. Eastern Time MaxCyte will host its third quarter 2026 earnings call today, November 10th, at 8:30 a.m.…GlobeNewswire
- MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue BaseROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and…GlobeNewswire
- MaxCyte to Participate in Three Upcoming Investor ConferencesROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and…GlobeNewswire
- MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue GuidanceMaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026GlobeNewswire
- Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue EstimatesKymera Therapeutics (KYMR) delivered earnings and revenue surprises of +3.13% and +67.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqKYMR, MXCT